publicFounded 2013
CRISPR Therapeutics
Funding Summary
Total Funding
$1.5B+
Latest Valuation
~$4B (public market cap)
About
Co-developed Casgevy (exa-cel) with Vertex Pharmaceuticals — the first CRISPR-based therapy approved by the FDA (December 2023) for sickle cell disease and transfusion-dependent beta-thalassemia.
Products
casgevycrispr-cell-therapy
Recent Developments
Recent developments are auto-populated from tagged articles in the Newsfeed. Browse all news →